Background: Montelukast, a leucotriene receptor antagonist, binds the cysteinyl leucotriene type 1 receptor. Montelukast is commonly prescribed to asthma patients as add-on therapy to inhaled corticosteroids. Several clinical trials emphasized that montelukast can be considered a safe drug. However, recent evidence reconsidered the benefit/risk ratio of the use of montelukast for both paediatric and adult patients. Summary: The present review analyzed the previous published case reports regarding montelukast-induced adverse drug reactions (ADRs). They included agitation, anxiety, depression, sleep disturbance, hallucinations, suicidal thinking and suicidality, tremor, dizziness, drowsiness, neuropathies and seizures. The immune system can be involved, in particular, cases of Churg-Strauss syndrome have been published. Furthermore, it can induce hypersensitivity reactions, including anaphylaxis and eosinophilic infiltration. In addition, hepatobiliary, pancreatic and uropoietic disorders have been observed. Some of these cases are characterized by severe prognosis (i.e. neurological deficit and fatal hepatotoxicity). Key Message: The use of montelukast can be burdened by several ADRs, of which physicians should be aware in their clinical practice. A better understanding of the mechanisms causing ADRs after using montelukast could help researchers and clinicians in defining a risk-reduction strategy aimed to lessen montelukast toxicity. More accurate epidemiological studies, in order to discover risk factors favouring montelukast-associated ADRs, are demanded.

Keywords:
Montelukast, Adverse drug reaction, Anti-leucotrienes, Allergy, Asthma, Hypersensitivity, Pharmacovigilance, Churg-Strauss syndrome, Toxicity
1.
Peters-Golden M, Gleason MM, Togias A: Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006;36:689-703.
2.
Fal AM, Kopec A: Status of leukotrienes in the pathophysiology of asthma. Necessity for antileukotrienes treatment (in Polish). Pneumonol Alergol Pol 2010;78:68-73.
3.
Shirasaki H, Kanaizumi E, Seki N, Fujita M, Kikuchi M, Himi T: Localization and up-regulation of cysteinyl leukotriene-2 receptor in human allergic nasal mucosa. Allergol Int 2013;62:223-228.
4.
Kanda T, Tanio H, Wu C, Nishihara H, Nogaki F, Ono T: Churg-Strauss syndrome with severe granulomatous angiitis and crescentic glomerulonephritis, which developed during therapy with a leukotriene receptor antagonist. Clin Exp Nephrol 2010;14:602-607.
5.
Sircar G, Saha B, Bhattacharya SG, Saha S: Allergic asthma biomarkers using systems approaches. Front Genet 2014;4:308.
6.
Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-478.
7.
Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, Schneider A: Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008;63:453-462.
8.
Haselkorn T, Chen H, Miller DP, Fish JE, Peters SP, Weiss ST, Jones CA: Asthma control and activity limitations: insights from the Real-world Evaluation of Asthma Control and Treatment (REACT) study. Ann Allergy Asthma Immunol 2010;104:471-477.
9.
Bozek A, Jarzab J: Adherence to asthma therapy in elderly patients. J Asthma 2010;47:162-165.
10.
Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS, Schellenberg RR, McIvor RA: Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009;16(suppl A):17A-31A.
11.
Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, Knorr B, Noonan G: Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009;44:568-579.
12.
Kroegel C: Global Initiative for Asthma (GINA) guidelines: 15 years of application. Expert Rev Clin Immunol 2009;5:239-249.
13.
Chauhan BF, Ben Salah R, Ducharme FM: Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. Cochrane Database Syst Rev 2013;10:CD009585.
14.
Chauhan BF, Ducharme FM: Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012;5: CD002314.
15.
Pagnoux C: Churg-Strauss syndrome: evolving concepts. Discov Med 2010;9:243-252.
16.
Camargo CA Jr, Gurner DM, Smithline HA, Chapela R, Fabbri LM, Green SA, Malice MP, Legrand C, Dass SB, Knorr BA, Reiss TF: A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol 2010;125:374-380.
17.
Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P: Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
18.
Bibby S, Healy B, Steele R, Kumareswaran K, Nelson H, Beasley R: Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax 2010;65:132-138.
19.
Villena V, Hidalgo R, Sotelo MT, Martin-Escribano P: Montelukast and Churg-Strauss syndrome. Eur Respir J 2000;15:626.
20.
Goransson LG, Omdal R: A severe systemic inflammatory reaction following therapy with montelukast (Singulair). Nephrol Dial Transplant 2000;15:1054-1055.
21.
Solans R, Bosch J, Selva A, Orriols R, Vilardell M: Montelukast and Churg-Strauss syndrome. Thorax 2002;57:183-185.
22.
Michael AB, Murphy D: Montelukast-associated Churg-Strauss syndrome. Age Ageing 2003;32:551-552.
23.
Cuchacovich R, Justiniano M, Espinoza LR: Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA). Clin Rheumatol 2007;26:1769-1771.
24.
Currie GP, McKinlay L, Kerr KM: Histological appearances of putative montelukast related Churg-Strauss syndrome. Thorax 2008;63:1120.
25.
Girszyn N, Amiot N, Lahaxe L, Cuvelier A, Courville P, Marie I: Churg-Strauss syndrome associated with montelukast therapy. QJM 2008;101:669-671.
26.
Jennings L, Ho WL, Gulmann C, Murphy GM: Churg-Strauss syndrome secondary to antileucotriene therapy in a patient not receiving oral corticosteroids. Clin Exp Dermatol 2009;34:e430-e431.
27.
Man MA, Alexandrescu D, Pop M, Trofor A: Churg Strauss syndrome associated with montelukast - case report. Pneumologia 2012;61:113-116.
28.
Wechsler ME, Finn D, Gunawardena D, Westlake R, Barker A, Haranath SP, Pauwels RA, Kips JC, Drazen JM: Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest Journal 2000;117:708-713.
29.
Matsui K, Nishijima K: A case of montelukast-induced Churg-Strauss syndrome associated with liver dysfunction. Case Reports in Hepatology 2011, DOI:
https://doi.org/10.1155/2011/412524
.
30.
Anar C, Unsal I, Ozanturk ME, Halilcolar H, Yucel N: A case of Churg-Strauss syndrome treated with montelukast. Med Princ Pract 2012;21:186-189.
31.
Franco J, Artés MJ: Pulmonary eosinophilia associated with montelukast. Thorax 1999;54:558-560.
32.
Tuggey JM, Hosker HS: Churg-Strauss syndrome associated with montelukast therapy. Thorax 2000;55:805-806.
33.
Carlesimo M, Mari E, Palese E, Pranteda G, Camplone G: Churg-Strauss and montelukast. Int J Immunopathol Pharmacol 2011;24:1079-1082.
34.
Black JG, Bonner JR, Boulware D, Andea AA: Montelukast-associated Churg-Strauss vasculitis: another associated report. Ann Allergy Asthma Immunol 2009;102:351-352.
35.
Conen D, Leuppi J, Bubendorf L, Ronsdorf A, Tamm M, Hauser T: Montelukast and Churg-Strauss syndrome. Swiss Med Wkly 2004;134:377-380.
36.
Zandman-Goddard G, Sylantiev C, Langevitz P: Montelukast-related Churg-Strauss vasculitis presenting with peripheral neuropathy. Isr Med Assoc J 2007;9:50-51.
37.
Guilpain P, Viallard JF, Lagarde P, Cohen P, Kambouchner M, Pellegrin JL, Guillevin L: Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology 2002;41:535-539.
38.
Mukhopadhyay A, Stanley NN: Churg-Strauss syndrome associated with montelukast. Postgrad Med J 2001;77:390-391.
39.
Uyar M, Elbek O, Bakir K, Kibar Y, Bayram N, Dikensoy O: Churg-Strauss syndrome related to montelukast. Tuberk Toraks 2012;60:56-58.
40.
Manalai P, Woo JM, Postolache TT: Suicidality and montelukast. Expert Opin Drug Saf 2009;8:273-282.
41.
Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B: Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691-696.e6.
42.
Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA: Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study. J Allergy Clin Immunol 2012;130:368-375.
43.
Wallerstedt SM, Brunlof G, Sundstrom A, Eriksson AL: Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009;18:858-864.
44.
Anandan N, Ibitoye F: Montelukast and worsening of hallucinations in paranoid schizophrenia. Psychiatric Bulletin 2008;32:276-276.
45.
Ibarra-Barrueta O, Palacios-Zabalza I, Mora-Atorrasagasti O, Mayo-Suarez J: Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events. Ann Pharmacother 2014;48:145-148.
46.
Cereza G, Garcia Dolade N, Laporte JR: Nightmares induced by montelukast in children and adults. Eur Respir J 2012;40:1574-1575.
47.
Callero-Viera A, Infante S, Fuentes-Aparicio V, Zapatero L, Alonso-Lebrero E: Neuropsychiatric reactions to montelukast. J Investig Allergol Clin Immunol 2012;22:452-453.
48.
Byrne F, Oluwole B, Whyte V, Fahy S, McGuinness D: Delayed onset of neuropsychiatric effects associated with montelukast. Ir J Psych Med 2012;29:125-127.
49.
Kocyigit A, Gulcan Oksuz B, Yarar F, Uzun F, Igde M, Islek I: Hallucination development with montelukast in a child with asthma: case presentation. Iran J Allergy Asthma Immunol 2013;12:397-399.
50.
Alkhuja S, Gazizov N, Alexander ME: Sleeptalking! Sleepwalking! Side effects of montelukast. Case Rep Pulmonol 2013;2013:813786.
51.
Palodhi S, Ray Chaudhuri P, Biswas A, Bera T: Montelukast induced hypertriglyceridemia. Indian Med Gaz 2012;146:334-336.
52.
Harugeri A, Parthasarathi G, Sharma J, D'Souza GA, Ramesh M: Montelukast induced acute hepatocellular liver injury. J Postgrad Med 2009;55:141-142.
53.
Russmann S, Iselin HU, Meier D, Zimmermann A, Simon HU, Caduff P, Reichen J: Acute hepatitis associated with montelukast. J Hepatol 2003;38:694-695.
54.
Incecik F, Onlen Y, Sangun O, Akoglu S: Probable montelukast-induced hepatotoxicity in a pediatric patient: case report. Ann Saudi Med 2007;27:462-463.
55.
Actis GC, Bugianesi E, Ottobrelli A, Rizzetto M: Fatal liver failure following food supplements during chronic treatment with montelukast. Dig Liver Dis 2007;39:953-955.
56.
Das S, Mondal S, Dey JK, Bandyopadhyay S, Saha I, Tripathi SK: A case of montelukast induced hypercholesterolemia, severe hypertriglyceridemia and pancreatitis. J Young Pharm 2013;5:64-66.
57.
Cetkovska P, Pizinger K: Childhood pemphigus associated with montelukast administration. Clin Exp Dermatol 2003;28:328-329.
58.
Minciullo PL, Saija A, Bonanno D, Ferlazzo E, Gangemi S: Montelukast-induced generalized urticaria. Ann Pharmacother 2004;38:999-1001.
59.
Tedeschi A: Paradoxical exacerbation of chronic urticaria by H1-antihistamines and montelukast. Eur Ann Allergy Clin Immunol 2009;41:187-189.
60.
Herzinger T, Ludolph-Hauser D, Przybilla B: Urticaria triggered by antiallergy treatment. Clin Exp Dermatol 2008;33:519-520.
61.
Sabbagh R, Sheikh-Taha M: Possible montelukast-induced angioedema. Am J Health Syst Pharm 2009;66:1705-1706.
62.
Aypak C, Turedi O, Solmaz N, Yikilkan H, Gorpelioglu S: A rare adverse effect of montelukast treatment: ecchymosis. Respir Care 2013;58:e104-e106.
63.
Tayeb MMS: Allergy to montelukast sodium treated effectively by protracted oral desensitization: first case report. J Aller Ther 2013;4:2.
64.
Xie JX, Wei JF, Meng L: Montelukast sodium-induced hematuria: a case report and literature review of 19 cases in mainland China. Int J Clin Pharmacol Ther 2013;51:958-962.
65.
Ducharme FM, Lasserson TJ, Cates CJ: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2011:CD003137.
66.
Scichilone N, Battaglia S, Benfante A, Bellia V: Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients. Clin Interv Aging 2013;8:1329-1337.
67.
Singh RK, Tandon R, Dastidar SG, Ray A: A review on leukotrienes and their receptors with reference to asthma. J Asthma 2013;50:922-931.
68.
Ding Q, Fang SH, Zhou Y, Zhang LH, Zhang WP, Chen Z, Wei EQ: Cysteinyl leukotriene receptor 1 partially mediates brain cryoinjury in mice. Acta Pharmacol Sin 2007;28:945-952.
69.
Cuciureanu M, Căruntu ID, Păduraru O, Stoica B, Jerca L, Crauciuc E, Nechifor M: The protective effect of montelukast sodium on carbon tetrachloride induced hepatopathy in rat. Prostaglandins Other Lipid Mediat 2009;88:82-88.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.